Adherence with medications used to treat osteoporosis: Behavioral insights

Current Osteoporosis Reports

Volumn 11, Issue 1, 2013, Pages 21-29

  Schousboe, John T ^a,b  

^a PARK NICOLLET INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Beliefs about medications; Medication compliance; Medication persistence; Osteoporotic fractures

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; ZOLEDRONIC ACID;

AGING; ARTICLE; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DYSPEPSIA; FRACTURE; HEALTH BEHAVIOR; HUMAN; MEDICAL DECISION MAKING; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESCRIPTION; RISK ASSESSMENT; RISK REDUCTION; SMOKING; SOCIAL SUPPORT;

ATTITUDE TO HEALTH; BONE DENSITY CONSERVATION AGENTS; HEALTH BEHAVIOR; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PATIENT COMPLIANCE; PHYSICIAN-PATIENT RELATIONS; RISK FACTORS;

EID: 84882827100     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-013-0133-8     Document Type: Article

References (98)

1. • Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728-40. This descriptive study shows how medication use behavior to prevent futrue adverse health events is similar across numerous medications and target diseases.
2. World Health Organization. Adherence to long-term therapies: Evidence for action 2003. 2003.
3. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7.
4. Shah NR, Hirsch AG, Zacker C, Taylor S, Wood GC, Stewart WF. Factors associated with first-fill adherence rates for diabetic medications: a cohort study. J Gen Intern Med. 2009;24(2):233-7.
5. Shah NR, Hirsch AG, Zacker C, Wood GC, Schoenthaler A, Ogedegbe G, et al. Predictors of firstfill adherence for patients with hypertension. Am J Hypertens. 2009;22(4):392-6.
6. • Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284-90. This important study is the largest of the few showing the extent and importance of primary non-adherence to a variety of medications.
7. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82(12):1493-501.
8. Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int. 2012;23(3):1075-82.
9. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80(7):856-61.
10. Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract. 2006;12(5):522-8.
11. Weiss TW, Henderson SC, McHorney CA, Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin. 2007;23(9):2193-203.
12. Rossini M, Viapiana O, Gatti D, Adami S. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Clin Ther. 2009;31(7):1497-510.
13. Hadji P, Ziller V, Gamerdinger D, Spieler W, Articus K, Baier M, et al. Quality of life and health status with zoledronic acid and generic alendronate-a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int. 2012;23(7):2043-51.
14. Lee Y-K, Nho J-H, Ha Y-C, Koo K-H. Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int. 2012;23(9):2329-33.
15. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165(20):2414-9.
16. Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006;17(6):922-8.
17. Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J. 2006;99(6):570-5.
18. Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int. 2006;17(11):1638-44.
19. Landfeldt E, Strom O, Robbins S, Borgstrom F. Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA). Osteoporos Int. 2012;23(2):433-43. An important study showing the temporal relationship between non-persistence with fracture prevention medications and incident fractures, using a comprehensive national database.
20. Devine J, Trice S, Finney Z, Yarger S, Nwokeji E, Linton A, et al. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System. Osteoporos Int. 2012;23(4):1415-24.
21. Wamala S, Merlo J, Bostrom G, Hogstedt C, Agren G. Socioeconomic disadvantage and primary non-adherence with medication in Sweden. Int J Qual Health Care. 2007;19(3):134-40.
22. Papaioannou A, Ioannidis G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int. 2003;14(10):808-13.
23. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48(3):271-87.
24. Zambon A, Baio G, Mazzaglia G, Merlino L, Corrao G. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models. Pharmacoepidemiol Drug Saf. 2008;17(3):260-9.
25. Pressman A, Forsyth B, Ettinger B, Tosteson AN. Initiation of osteoporosis treatment after bone mineral density testing. Osteoporos Int. 2001;12(5):337-42.
26. Solomon DH, Levin E, Helfgott SM. Patterns of medication use before and after bone densitometry: factors associated with appropriate treatment. J Rheumatol. 2000;27(6):1496-500.
27. Rubin SM, Cummings SR. Results of bone densitometry affect women's decisions about taking measures to prevent fractures. Ann Intern Med. 1992;116(12 Pt 1):990-5.
28. Silverman SL, Greenwald M, Klein RA, Drinkwater BL. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol. 1997;89(3):321-5.
29. Pickney CS, Arnason JA. Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int. 2005;16(9):1156-60.
30. Berecki-Gisolf J, Hockey R, Dobson A. Adherence to bisphosphonate treatment by elderly women. Menopause. 2008;15(5):984-90.
31. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin. 2008;24(5):1337-44.
32. Gould ON, McDonald-Miszcak L, King B. Metacognition and medication adherence: how do older adults remember? Exp Aging Res. 1997;23:315-42.
33. Rosen MI, Beauvais JE, Rigsby MO, Salahi JT, Ryan CE, Cramer JA. Neuropsychological correlates of suboptimal adherence to metformin. J Behav Med. 2003;26(4):349-60.
34. Gray SL, Mahoney JE, Blough DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 2001;35(5):539-45.
35. Salas M, In't Veld BA, van der Linden PD, Hofman A, Breteler M, Stricker BH. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin Pharmacol Ther. 2001;70(6):561-6.
36. Kiortsis DN, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipidlowering drugs in hyperlipidemic patients. J Clin Pharm Ther. 2000;25(6):445-51.
37. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14(4):571-81.
38. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-22.
39. • Patrick AR, Brookhart MA, Losina E, Schousboe JT, Cadarette SM, Mogun H, et al. The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab. 2010;95(7):3251-9. The most detailed study to date exploring the details of the relationship between level and adherence to fracture prevention medication and incident fractures.
40. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19(6):811-8.
41. Sheehy O, Kindundu C, Barbeau M, LeLorier J. Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int. 2009;20(9):1583-94.
42. Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011;17(1):25-39.
43. Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int. 2008;19(10):1421-9.
44. Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int. 2011;22(3):943-54.
45. Curtis JR, Larson JC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R, et al. Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. Med Care. 2011;49(5):427-35.
46. Curtis JR, Delzell E, Chen L, Black D, Ensrud K, Judd S, et al. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res. 2011;26(4):683-8.
47. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115(3):209-16.
48. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14(3):259-62.
49. Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17(6):914-21.
50. Britten N, Ukoumunne OC, Boulton MG. Patients' attitudes to medicines and expectations for prescriptions. Health Expect. 2002;5(3):256-69.
51. Unson CG, Siccion E, Gaztambide J, Gaztambide S, Mahoney Trella P, Prestwood K. Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health (Larchmt). 2003;12(10):1037-45.
52. Britten N. Patients' ideas about medicines: a qualitative study in a general practice population. Br J Gen Pract. 1994;44(387):465-8.
53. Lin EH, Von Korff M, Ludman EJ, Rutter C, Bush TM, Simon GE, et al. Enhancing adherence to prevent depression relapse in primary care. Gen Hosp Psychiatry. 2003;25(5):303-10.
54. Benson J, Britten N. Patients' decisions about whether or not to take antihypertensive drugs: qualitative study. BMJ. 2002;325(7369):873.
55. Horne R, Weinman J, Hankins M. The Beliefs about Medications Questionnaire: the development of a new method for assessing the cognitive representation about medication. Psychol Health. 1999;14:1-24.
56. Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med. 1992;34(5):507-13.
57. Conrad P. The meaning of medications: another look at compliance. Soc Sci Med. 1985;20(1):29-37.
58. Shoemaker SJ, de Oliveira DR, Alves M, Ekstrand M. The medication experience: Preliminary evidence of its value for patient education and counseling on chronic medications. Patient Educ Couns. 2011;83(3):443-50.
59. Adams S, Pill R, Jones A. Medication, chronic illness and identity: the perspective of people with asthma. Soc Sci Med. 1997;45(2):189-201.
60. Dowell J, Hudson H. A qualitative study of medication-taking behaviour in primary care. Fam Pract. 1997;14(5):369-75.
61. • Sale JEM, Gignac MA, Hawker G, Frankel L, Beaton D, Bogoch E, et al. Decision to take osteoporosis medication in patients who have had a fracture and are 'high' risk for future fracture: a qualitative study. BMC Musculoskelet Disord. 2011;12:92. An important detailed descriptive study of how patients decide whether or not to accept a recommended prescription for fracture prevention medication.
62. Janz N, Becker M. The health belief model: a decade later. Heal Educ Q. 1984;11(1):1-47.
63. Connor M, Sparks P. The theory of planned behavior and health behaviors. In: Connor M, Norman P, editors. Predicting health behavior. Philadelphia: Open University Press; 1995. p. 121-62.
64. Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: using common sense to understand treatment adherence and affect cognitive interactions. Cogn Ther Res. 1992;16(2):143-63.
65. Bandura A. Social foundations of thought and action. A social cognitive theory. Englewood Cliffs: Prentice-Hall, Inc.; 1986.
66. Buglar ME, White KM, Robinson NG. The role of self-efficacy in dental patients' brushing and flossing: testing an extended Health Belief Model. Patient Educ Couns. 2010;78(2):269-72.
67. Bylund CL, Galvin KM, Dunet DO, Reyes M. Using the extended health belief model to understand siblings' perceptions of risk for hereditary hemochromatosis. Patient Educ Couns. 2011;82(1):36-41.
68. Gillibrand R, Stevenson J. The extended health belief model applied to the experience of diabetes in young people. Br J Health Psychol. 2006;11(Pt 1):155-69.
69. Cline RR, Farley JF, Hansen RA, Schommer JC. Osteoporosis beliefs and antiresorptive medication use. Maturitas. 2005;50(3):196-208.
70. McHorney CA, Schousboe JT, Cline RR, Weiss TW. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin. 2007;23(12):3137-52.
71. Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med. 2008;23(11):1815-21.
72. • Schousboe JT, Dowd BE, Davison ML, Kane RL. Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int. 2010;21(11):1899-909. This study is unique in that it shows the relative importance of different medication attitudes and beliefs, included perceived self efficacy on self-reported persistence and compliance with fracture prevention medications.
73. • Schousboe JT, Davison ML, Dowd B, Thiede Call K, Johnson P, Kane RL. Predictors of patients' perceived need for medication to prevent fracture. Med Care. 2011;49(3):273-80. This studyis unique in that it illustrates the relative importance of the quality of the patientphysician relationship and objective indicators of fracture risk, adjusted for each other, on patient perceived necessity of fracture prevention medication.
74. Solomon DH, Brookhart MA, Tsao P, Sundaresan D, Andrade SE, Mazor K, et al. Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule. Osteoporos Int. 2011;22(6):1737-43.
75. Bandura A. Human agency in social cognitive theory. Am Psychol. 1989;44(9):1175-84.
76. Resnick B, Wehren L, Orwig D. Reliability and validity of the self-efficacy and outcome expectations for osteoporosis medication adherence scales. Orthop Nurs. 2003;22(2):139-47.
77. Bloom G, Standing H, Lloyd R. Markets, information asymmetry and health care: towards new social contracts. Soc Sci Med. 2008;66(10):2076-87.
78. Thorne SE, Robinson CA. Reciprocal trust in health care relationships. J Adv Nurs. 1988;13(6):782-9.
79. Hall MA, Dugan E, Zheng B, Mishra AK. Trust in physicians and medical institutions: what is it, can it be measured, and does it matter? Milbank Q. 2001;79(4):613-39. v.
80. Goff SL, Mazor KM, Meterko V, Dodd K, Sabin J. Patients' beliefs and preferences regarding doctors' medication recommendations. J Gen Intern Med. 2008;23(3):236-41.
81. Buller M, Buller D. Physicians' communication style and patient satisfaction. J Heal Soc Behav. 1987;28:375-88.
82. Charles C, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med. 1999;49(5):651-61.
83. Jahng KH, Martin LR, Golin CE, DiMatteo MR. Preferences for medical collaboration: patientphysician congruence and patient outcomes. Patient Educ Couns. 2005;57(3):308-14.
84. • Douglas F, Petrie KJ, Cundy T, Horne A, Gamble G, Grey A. Differing perceptions of intervention thresholds for fracture risk: a survey of patients and doctors. Osteoporos Int. 2012;23(8):2135-40. This study is an important, recent documentation of how patients and physicians perceive fracture risks and use of medications to lower those risks differently.
85. Cadarette SM, Carney G, Baek D, Gunraj N, Paterson JM, Dormuth CR. Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. Osteoporos Int. 2012;23(4):1475-80.
86. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650-5.
87. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-50.
88. Zafran N, Liss Z, Peled R, Sherf M, Reuveni H. Incidence and causes for failure of treatment of women with proven osteoporosis. Osteoporos Int. 2005;16(11):1375-83.
89. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-310.
90. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150(9):1881-4.
91. Wroe AL. Intentional and unintentional nonadherence: a study of decision making. J Behav Med. 2002;25(4):355-72.
92. Silverman SL, Schousboe JT, Gold DT. Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int. 2011;22(1):21-6.
93. Kripalani S, Gatti ME, Jacobson TA. Association of age, health literacy, and medication management strategies with cardiovascular medication adherence. Patient Educ Couns. 2010;81(2):177-81.
94. Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med. 2011;155(2):97-107.
95. Elliott RA, Shinogle JA, Peele P, Bhosle M, Hughes DA, Elliott RA, et al. Understanding medication compliance and persistence from an economics perspective. Value Health. 2008;11(4):600-10.
96. Roelofsma PH, van der Pligt J. On the psychology of time preference and human decisions: introduction to the special issue. Acta Psychol (Amst). 2001;108(2):91-3.
97. Read D, Loewenstein G. Time and decision: introduction to the special issue. J Behav Decis Mak. 2000;13:141-4.
98. Sozou PD, Seymour RM, Sozou PD, Seymour RM. Augmented discounting: interaction between ageing and time-preference behaviour. Proc R Soc London, Ser B. 2003;270(1519):1047-53.